Section snippets

Funding Support and Author Disclosures

Dr Warraich has served on the medical advisory board for GoodRx. Dr Krumholz is the Editor-in-Chief of JACC; has received stock options for advisory roles from Element Science and Identifeye; has received payments for advisory roles from F-Prime; is a cofounder of and holds equity in Hugo Health, Refactor Health, and ENSIGHT-AI; and is associated with research contracts through Yale University from Janssen, Kenvue, Novartis, and Pfizer. Dr Califf has been an employee of and held equity in

中文翻译：

---

让心血管临床医生在证据生成中发声：FDA 和 JACC 之间的合作

 部分片段

资金支持和作者披露

Warraich 博士曾在 GoodRx 的医疗顾问委员会任职。Krumholz 博士是 JACC 的主编;已获得 Element Science 和 Identifeye 的顾问股票期权;已收到 F-Prime 的顾问职位报酬;是 Hugo Health、Refactor Health 和 ENSIGHT-AI 的联合创始人并持有其股权;并与耶鲁大学与 Janssen、Kenvue、Novartis 和 Pfizer 的研究合同相关联。Califf 博士一直是